This study is looking at a condition called bronchiectasis, which is a lung disease where the airways become damaged and widened, making it difficult to clear mucus and leading to repeated lung infections. People with this condition often experience frequent flare-ups of their symptoms, called exacerbations, which can include increased cough, more mucus production, and breathing difficulties. The study will test a medication called GSK3862995B, which is a biologic treatment given as an injection under the skin. Some participants will receive the actual medication while others will receive a placebo. The study will also use 5% Dextrose Injection, which is a simple sugar solution given through injection.
The purpose of the study is to evaluate how well GSK3862995B works compared with placebo in people with bronchiectasis. The study will look at whether the medication can reduce the number of times patients experience flare-ups of their condition over time. The study will also examine the safety of the medication, how the body’s immune system responds to it, and how the medication moves through and is processed by the body.
During this study, participants will receive repeated doses of either GSK3862995B or placebo over a period of time. The study is designed so that neither the participants nor the doctors will know who is receiving the actual medication and who is receiving the placebo until the study is completed. Throughout the study, doctors will monitor how often participants experience flare-ups of their bronchiectasis, how long it takes before the first flare-up occurs, and how many severe flare-ups happen. The study is expected to continue until late 2027.
Denmark 
France 
Germany 
Italy 
Poland 
Spain 
